Active Ingredient: Glibenclamide
Glibenclamide is is a sulphonylurea hypoglycaemic agent, indicated for the oral treatment of patients with non-insulin dependent diabetes who respond inadequately to dietary measures alone.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Oral, between 2.5 milligrams glibenclamide and 5 milligrams glibenclamide, once daily to breakfast, over the duration of 1 to 2 weeks. Afterwards, oral, between 2.5 milligrams glibenclamide and 15 milligrams glibenclamide, daily to meals, 1 to 2 doses in total. The maximum allowed total dose is 15 milligrams glibenclamide daily.
The dosage of glibenclamide is governed by the desired blood glucose level.
The dosage of glibenclamide must be the lowest possible dose which is effective.
Mistakes, e.g. forgetting to take a dose, must never be corrected by subsequently taking a larger dose.
The usual total daily dosage is 2.5 mg to 15 mg daily with a usual initial dose of 5 mg daily. Weekly adjustments can be made to increase the dosage to the optimal level. Doses of 10 mg or less may be taken as a single dose immediately before breakfast, but should the daily dose exceed 10 mg, the remainder should be taken immediately before the evening meal.
The elderly usually require lower dosage.
A physician should be consulted in the event that a dose has not been taken at the prescribed time, a meal has been skipped or an extra dose has been taken.
It is very important not to skip meals after the tablets have been taken.
As an improvement in control of diabetes is, in itself, associated with higher insulin sensitivity, glibenclamide requirements may fall as treatment proceeds. To avoid hypoglycaemia, timely dose reduction or cessation of glibenclamide therapy must therefore be considered.
Correction of dosage must also be considered, whenever:
Change over from other oral antidiabetic agents to glibenclamide should be done under the supervision of a specialist, and due to the potential summation of effects of both medications, entails a risk of hypoglycaemia. A break from medication may therefore be required when changing over medications. This should be decided by the attending physician.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
